| Article Access Statistics|
| Viewed||2339 |
| Printed||82 |
| Emailed||2 |
| PDF Downloaded||240 |
| Comments ||[Add] |
| Cited by others ||5 |
Click on image for details.
|Year : 2012 | Volume
| Issue : 3 | Page : 248-252
Atypical antipsychotics usage in long-term follow-up of first episode schizophrenia
Amresh Shrivastava1, Megan Johnston2, Kristen Terpstra3, Larry Stitt4, Nilesh Shah5
1 Department of Psychiatry, Elgin Early Intervention Program for Psychosis, The University of Western Ontario, Ontario, Canada, and Mental Health Resource Foundation, Mumbai, Maharashtra, India
2 Department of Psychology, University of Toronto, 100 St. George, Toronto, Ontario, M5S 3G3, Canada
3 Department of Psychology, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, N6A 5C1, Canada
4 Department of Epidemiology & Biostatistics, Schulich School of Medicine and Dentistry, The University of Western Ontario, London, Ontario, N6A 5C1, Canada
5 LTMG Medical College University of Mumbai, Maharashtra, India
Background: It is not clear if the role of antipsychotics in long-term clinical and functional recovery from schizophrenia is correlated. The pattern of use is a major aspect of pharmacotherapy in long-term follow-ups of schizophrenia. The aim of this study was to examine patterns of antipsychotic usage in patients with longstanding psychosis and their relationship to social outcomes.
Materials and Methods: We conducted a cross-sectional study on a cohort from a long-term outcome study. Participants were 116 first episode schizophrenia patients from Mumbai, India, who had more than 80% compliance, as reported by relatives. Patients were assessed on antipsychotic medication use and on clinical and functional parameters.
Results: There was a high compliance rate (72%). Most patients (77%) used atypical antipsychotics; only 10 (8.6%) patients were taking typical antipsychotics. There were no among-drug differences in the percentage of patients meeting the recommended dose: Clozapine (200-500 mg), Riseperidone (4.0-6.0 mg), Olanzapine (10-20 mg), Quetiapine (400-800 mg), Aripiprazole (15-30 mg), Ziprasidone (120-160 mg); an equivalent dosage of Chlorpromazine (300-600 mg) did not differ amongst any atypical antipsychotic subgroup. Also, we did not find any significant differences in recovery on Clinical Global Impression Severity scale (CGIS), Quality of Life (QOL), or Global Assessment of Functioning (GAF) between groups of antipsychotic drugs.
Conclusion: This study shows that most patients suffering from schizophrenia, in a long-term follow-up, use prescribed atypical antipsychotics within the recommended limits. Also, the chlorpromazine equivalence dosages do not differ across antipsychotic medications. The outcomes on clinical and functional parameters are also similar across all second-generation antipsychotics.
Regional Mental Health Care, 467 Sunset Drives, St. Thomas, Ontario, N5H 3V9, The University of Western Ontario, London, Canada
Source of Support: None, Conflict of Interest: None
[FULL TEXT] [PDF]*